Abstract
The first example of an inhibitor of the kinase TAK1 that binds in the DFG-out conformation is disclosed. These preliminary studies used kinase-targeted screening and structure-based drug design to create a molecule with dual pharmacological inhibition of p38 and TAK1 that demonstrated significant activity in a cell-based, anti-inflammatory assay. The first example of an inhibitor of the kinase TAK1 that binds in the DFG-out conformation is disclosed. These preliminary studies used kinase-targeted screening and structure-based drug design to create a molecule with dual pharmacological inhibition of p38 and TAK1 that demonstrated significant activity in a cell-based, anti-inflammatory assay.
Original language | English |
---|---|
Pages (from-to) | 500-505 |
Number of pages | 6 |
Journal | Chemical Biology and Drug Design |
Volume | 82 |
Issue number | 5 |
Early online date | 16 Oct 2013 |
DOIs | |
Publication status | Published - 1 Nov 2013 |
Keywords
- Chemical biology
- Drug design
- Kinase
- Phosphatase
- Structure-based drug design
- X-ray crystallography
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine